ProCE Banner Events

Share

Personalized Treatment in Myelofibrosis: Applying the Data to Address Barriers and Improve Care

Learn from expert faculty as they discuss best practices in the care of patients with myelofibrosis, including evidence-based treatment options, symptom and toxicity management, and monitoring. Join us at 3:00-3:30 PM Pacific Time (PT) for in-person registration or at 3:30 PM PT online when the symposium beings. 

Pharmacists: 1.50 contact hours (0.15 CEUs)

This event has expired. No longer available for credits.

Who Should Attend

The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with myelofibrosis as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Time and location

Sunday, April 30, 2023

3:30 PM - 5:00 PM Pacific Time (PT)

In-personVirtual

Asembia’s AXS23 Summit at Wynn Las Vegas
3131 Las Vegas Blvd. S
Las Vegas, Nevada 89109

Margaux 1

Faculty
Emily Hollinghurst, PharmD, BCOP, CSP, APh

Assistant Professor
Department of Pharmacy Practice
Loma Linda University, School of Pharmacy
Clinical Pharmacy Specialist
Specialty Pharmacy Services
Loma Linda University Medical Center
Loma Linda, California

Victoria Nachar, PharmD, BCOP

Clinical Pharmacist Specialist, Hematology
University of Michigan Rogel Cancer Center
Ann Arbor, Michigan

Agenda

In-person Registration: 3:00-3:30 PM Pacific Time (PT)

Presentation: 3:30 - 5:00 PM Pacific Time (PT)

- Welcome and Opening Remarks 

- Personalized Medication Therapy for Management of Myelofibrosis 

- Minimizing the Impact and Management of Treatment-Related Adverse Events 

- Specialty Pharmacy Strategies for Optimizing Care 

- Question and Answer Session

Location

Venue Name

Asembia’s AXS23 Summit at Wynn Las Vegas

Address

Asembia’s AXS23 Summit at Wynn Las Vegas
3131 Las Vegas Blvd. S
Las Vegas, Nevada 89109

Room Name

Margaux 1

CME/CE Info

Goal Statement
The goal of this activity is to improve the knowledge and competence of learners about medication therapy management of myelofibrosis.

Target Audience
The target audience for this activity is pharmacists—including specialty, managed care, and clinical pharmacists—who care for patients with myelofibrosis as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Discuss myelofibrosis risk-stratification, symptom assessment, and therapy response evaluation
  • Develop evidence-based first- and second-line, risk-informed treatment plans for myelofibrosis that incorporates the latest clinical trial evidence into therapy selection and sequencing
  • Develop strategies to improve patient quality of life by minimizing disease symptoms and treatment-related toxicities
  • Implement a patient management program to ensure appropriate outcomes monitoring for therapy responsiveness and adverse events in patients receiving therapy for myelofibrosis

Accreditation

CE Accreditation

Pharmacists

This activity is jointly provided by ProCE, LLC and Clinical Care Options, LLC. ProCE, LLC is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. ACPE Universal Activity Number 0221-9999-23-011-L01-P has been assigned to this live application-based activity (initial release date 4/30/2023). This activity is approved for 1.5 contact hours (0.15 CEUs) in states that recognize ACPE providers. This activity is provided at no cost to participants. Participants must complete the online post-test and activity evaluation within 30 days of the activity to receive pharmacy CE credit. No partial credit will be given. Statements of completion will be issued online at www.ProCE.com, and proof of completion will be posted in NABP CPE Monitor profiles.

Disclosure
ProCE requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to ProCE policy. ProCE is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.

Acknowledgement

Provided by ProCE, LLC, in partnership with Clinical Care Options, LLC

This educational activity is supported by an educational grant from GSK.

Program Learning Goal

The goal of this activity is to improve the knowledge and competence of learners about medication therapy management of myelofibrosis.

Partner

Clinical Care Options, LLC

ProCE Banner

Contact Information

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address:


Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Additional Information

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact meetings@clinicaloptions.com prior to the live event.